Study to Evaluate the Reduction of Cardiac Problems in Multiple Sclerosis Patients With Mitoxantrone and Dexrazoxane in Combination

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-04-30

Study Completion Date

2016-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will primarily address the question whether the combination of Mitoxantrone therapy with dexrazoxane can reduce cardiotoxic side effects in the treatment of Multiple Sclerosis patients in comparison to Mitoxantrone monotherapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Disease-Modifying Treatments for Myasthenia Gravis

NCT03490539

Neurological Disorder Autoimmune Diseases

COMPLETED

Efficacy of Methotrexate in Myasthenia Gravis

NCT00814138

Myasthenia Gravis

COMPLETED PHASE2

CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases

NCT07337785

Relapsing or Refractory Multiple Sclerosis (MS) Myasthenia Gravis (MG) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) +1 more

RECRUITING EARLY_PHASE1

A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis

NCT01532869

Sclerosis, Systemic

COMPLETED PHASE3

A Study of Rituxan in the Treatment of Polyneuropathies Associated With Serum IgM Autoantibodies

NCT00006072

Peripheral Neuropathy

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

It is designed to provide clinical and paraclinical efficacy and safety data for dexrazoxane in Mitoxantrone treatment of Multiple Sclerosis in order to investigate the possible positive influence of dexrazoxane on cardiac function of Mitoxantrone-affected myocardial tissue and on the possible augmented clinical efficacy of Mitoxantrone in combination with dexrazoxane on neurological outcome parameters. The incidence of cardiotoxicity during combined Mitoxantrone/dexrazoxane treatment will be investigated and compared to the standard Mitoxantrone-treatment without dexrazoxane.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Sclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dexrazoxane (DRZ) plus Mitoxantrone (MX)

DRZ (600 mg/m2) : MX (12 mg/m2) ratio 50:1

Group Type EXPERIMENTAL

Dexrazoxane (DRZ) plus Mitoxantrone (MX)

Intervention Type DRUG

Dosage: DRZ (600 mg/m2) : MX (12 mg/m2) ratio 50:1 DRZ infusion / MX infusion once every three months over a period of 12 months, i.e. 5 infusions

Placebo plus Mitoxantrone (MX)

Placebo + MX (12 mg/m2)

Group Type PLACEBO_COMPARATOR

Placebo plus Mitoxantrone (MX)

Intervention Type DRUG

MX Dosage: 12mg/m2 Placebo infusion / MX infusion once every three months over a period of 12 months, i.e. 5 infusions

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dexrazoxane (DRZ) plus Mitoxantrone (MX)

Dosage: DRZ (600 mg/m2) : MX (12 mg/m2) ratio 50:1 DRZ infusion / MX infusion once every three months over a period of 12 months, i.e. 5 infusions

Intervention Type DRUG

Placebo plus Mitoxantrone (MX)

MX Dosage: 12mg/m2 Placebo infusion / MX infusion once every three months over a period of 12 months, i.e. 5 infusions

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Cardioxane® (Dexrazoxane) Ralenova® (Mitoxantrone) Ralenova ® (Mitoxantrone)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Written informed consent to participate in the study
* Male or female subject is 18 years of age to 55 years of age
* Subject must have one of the below mentioned confirmed diagnoses of Multiple Sclerosis: RRMS or CPMS according to rev. McDonald Criteria (2005)
* If female of childbearing potential: Will to practice reliable birth control measures during study treatment and for at least 6 months after completion of study medication; not lactating or pregnant; and has a documented negative pregnancy test result within 72 hours prior to study medication administration. Male study participants: Will to practice reliable birth control measures during study treatment and for at least 6 months after completion of study medication
* Subject is willing to participate in the study, follow protocol study treatment regimen, and comply with all planned assessments
* Mitoxantrone treatment indication is given according to current guidelines:

* Relapsing progressive or secondary progressive MS with/without superimposed relapses
* EDSS 3-6; EDSS deterioration ≥1 point over last 18 months or 2 relapses
* non-response or non-tolerability of pre-treatment

Exclusion Criteria

* Concomitant clinically suspected or confirmed neurologic disorder at study entry that may interfere with the evaluation in this protocol \[i.e. EDSS, MSFC, MEP or MRI measurements\]
* Pre-Treatment with DRZ or immunosuppressive drugs of the anthracycline family with cardiotoxic potential other than MX prior to study enrollment
* Last Treatment with MX within the past 84 days prior to study enrollment (regular 3-monthly intervals must be obtained)
* History of hypersensitivity to any of the study drugs or to drugs with similar chemical structures
* Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive HCG laboratory test (\>5 mIU/ml)
* Unwillingness to perform adequate contraception
* Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer
* Subjects unable or unwilling to adhere to the study-designated procedures and restrictions
* Patients not able to perform cardiac/neurological investigations including MRI, e.g. hypersensitivity to MRI contrast agent
* Other known contraindication for DRZ or MX according to current labelling
* Subject has a pre-existing cardiac disease interfering with left ventricular ejection fraction, i.e. cardiac insufficience for different reasons (resulting from prior cardial conditions such as myocardial infarction, myocarditis)
* Routine co-administration of cortisone-pulse therapy (other than for treatment of relapses), intrathecal triamcinolone-therapy or other off-label/ investigational agents (e.g. fampridine, aminopyridine)
* History of malignancy in the past 5 years (excluding localized basal cell carcinoma of the skin)
* Pre-Treatment with other immunosuppressive drugs (azathioprine, methotrexate, mycophenolate, cyclophosphamide) within the past 3 months
* Pre-Treatment with monoclonal antibodies (natalizumab, rituximab) within the past 6 months

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No